Raynovent_Life Sciences_YIJING CAPITAL

Home

Investment Portfolio

Frontier Technology

Life Sciences

About Us

Company Profile

Key Figures

Our Journey

Vision and Mission

Raynovent

Raynovent focused on developing and commercializing innovative therapies for respiratory and metabolic diseases. Leveraging deep expertise in disease pathophysiology, Raynovent targets key conditions including influenza, COVID-19, avian flu, idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and weight management

Back to List

We Look Forward to Hearing from You

Discovering talent, investing in the future, and growing with visionary entrepreneurs

Submit BP

Submit
BP

Submit BP

Yijing Capital focuses on innovative companies in frontier technology, life sciences, and related fields. Please complete the basic project information and upload the latest version of your business plan (BP). Our investment team will evaluate the materials and contact projects that align with our investment focus.

Company Name

Project Name

Sector

Funding Stage

Contact Person

Phone Number

Email Address

Project Overview

Business Plan Click to upload or drag and drop a file here
PDF only; maximum file size: 50 MB

CAPTCHA

Can't read it? Refresh

All submitted materials will be used solely for investment evaluation. We will strictly protect your business information.

Thank you for your trust in Yijing Capital.

We have received your business plan. After completing an initial evaluation, our investment team will contact projects that align with our investment focus. Due to the volume of submissions, we appreciate your understanding if you do not receive a follow-up. We wish your project every success!

This website uses cookies

This website uses cookies to improve your experience while you navigate through the website. You can choose to opt-out if you wish. For more information, please refer to our 《Cookies》。